| UC-CH47 | Breast carcinoma | Lung | Cardiopathy patient that received CIGB-247 simultaneous with QT (Capecitabine and Letrozol). | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on heart disease. |
| UC-CH77 | Breast carcinoma | Bones | Patient that received CIGB-247 simultaneous with QT (Capecitabine, Zoledronic acid) and Trastuzumab | Patient positive for anti-VEGF antibody response. |
| UC-CH49 | Ovary ADC | Peritoneum | Patient that received CIGB-247 simultaneous with QT (Docetaxel, Carboplatin) | Patient positive for anti-VEGF antibody response. |
| UC-HA03 | Ovary ADC | Contralateral ovary | Patient that received CIGB-247 simultaneous with QT (Paclitaxel, Carboplatin) and G-CSF | Patient positive for anti-VEGF antibody response. |
| UC-HA07 | Ovary ADC | Contralateral ovary | Patient that received CIGB-247 simultaneous with QT (Taxol, Cisplatin) | Patient positive for anti-VEGF antibody response. |
| UC-CQ108 | Bladder ADC | Lung | Patient that received CIGB-247 simultaneous with QT (Gemcitabine, Carboplatin) | Patient positive for anti-VEGF antibody response. |
| UC-CH10 | Hodgkin lymphoma | LN | Patient that received CIGB-247 simultaneous with QT (Procarbazine, Vincristine) and prednisone | Patient positive for anti-VEGF antibody response. |
| UC-CH11 | SCLC | Neck, contralateral pulmonary metastases | Patient that received CIGB-247 simultaneous with QT (Cisplatin, Etoposide (VP-16), taxol, vincristine) and G-CSF. | Patient positive for anti-VEGF antibody response. |
| UC-CQ105 | Rectum ADC | – | Vaccination with CIGB-247 was applied simultaneous with QT (Capecitabine) | Patient positive for anti-VEGF antibody response. |
| UC-HA01 | Peritoneum carcinoma | – | Patient that received CIGB-247 simultaneous with QT (Docetaxel, Paclitaxel) and submitted to a major abdominal surgery (phlegmon). | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on wound healing. |
| UC-CH22 | Breast carcinoma | Contralateral breast and LN | After fifth vaccination with CIGB-247, patient was submitted to urgency surgery (right tubo-ovarian abscess) and immunization was not interrupted. | Patient positive for anti-VEGF antibody response a. Physician did not report any negative incidence on wound healing. |
| UC-HA14 | Ovary ADC | – | Insulin-dependent diabetic patient with oral administration of metformin | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on diabetes condition. |
| UC-CH48 | Ovary carcinoma | Liver, brain, peritoneum | Patient diagnosed with diabetes mellitus | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on diabetes condition. |
| UC-CH08 | Malignant pleural mesothelioma | – | Cardiopathy patient with diabetes mellitus | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on chronic diseases. |
| UC-CH38 | Osteosarcoma | Lung | Patient with controlled-chronic bronchial asthma | Patient positive for anti-VEGF antibody response. |
| UC-CH25 | Cervix carcinoma | Liver and bones | Patient diagnosed with systemic lupus erythematosus | Patient positive for anti-VEGF antibody response. Physician did not report any negative incidence on autoimmune disease. |
| UC-CH46 | Thyroid carcinoma | LN and lung | Patient that received CIGB-247 simultaneous with oral levothyroxine | Patient positive for anti-VEGF antibody response. |
| UC-CQ116 | RCC | Lung | Patient that received CIGB-247 simultaneous with recombinant IFN-α2b | Patient positive for anti-VEGF antibody response. |
| UC-CQ111 | GBM | – | Patient that received CIGB-247 simultaneous with RT | Patient positive for anti-VEGF antibody response. |
